Ye-Xuan Cao1,2, Liang Li3, Hui-Wen Zhang1, Jing-Lu Jin1, Hui-Hui Liu1, Yuan-Lin Guo1, Na-Qiong Wu1, Cheng-Gang Zhu1, Qian Dong1, Rui-Xia Xu1, Jing Sun1, Jian-Jun Li1. 1. State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China. 2. Department of Cardiology, Beijing Chaoyang Hospital Affiliated to Capital University of Medical Science, Beijing, China. 3. Department of Surgical Intensive Care Unit, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center For Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College Beijing, Beijing, China.
Abstract
BACKGROUND: Visit-to-visit variability in lipid has been suggested as a predictor of major adverse cardiovascular events (MACEs). However, no evidence exists on the prognostic value of lipid variability in patients with familial hypercholesterolemia (FH). This prospective cohort study aimed to investigate whether lipid variability affects future MACEs in patients with FH receiving standard lipid-lowering therapy. METHODS: A total of 254 patients with FH were consecutively enrolled and followed for MACEs. Variability in the triglyceride, total cholesterol, high-density lipoprotein-cholesterol (HDL-C), low-density lipoprotein-cholesterol (LDL-C) and lipoprotein (a) [Lp(a)] were evaluated from 3 months after discharge using the standard deviation (SD), coefficient of variation (CV) and variability independent of the mean (VIM). RESULTS: During a mean follow-up of 49 months, 22 (8.7%) events occurred. Visit-to-visit variability in Lp(a) was significantly higher in the MACE group compared to the non-MACE group. In the multivariate Cox analysis, only Lp(a)-related parameters were independent predictors for MACEs. The hazard ratios and 95% confidence intervals of each 1-SD increase of SD, CV, and VIM of Lp(a) were 1.42 (1.12-1.80), 1.50 (1.11-2.02) and 1.60 (1.16-2.22), respectively. Kaplan-Meier analysis revealed that patients with higher Lp(a) variability presented lower event-free survival. The results were consistent in various subgroups. CONCLUSIONS: Our study firstly suggested that Lp(a) variability was associated with MACEs in real-world patients with FH, which emphasized the importance of regular lipid monitoring in the patients with high risk. 2021 Annals of Translational Medicine. All rights reserved.
BACKGROUND: Visit-to-visit variability in lipid has been suggested as a predictor of major adverse cardiovascular events (MACEs). However, no evidence exists on the prognostic value of lipid variability in patients with familial hypercholesterolemia (FH). This prospective cohort study aimed to investigate whether lipid variability affects future MACEs in patients with FH receiving standard lipid-lowering therapy. METHODS: A total of 254 patients with FH were consecutively enrolled and followed for MACEs. Variability in the triglyceride, total cholesterol, high-density lipoprotein-cholesterol (HDL-C), low-density lipoprotein-cholesterol (LDL-C) and lipoprotein (a) [Lp(a)] were evaluated from 3 months after discharge using the standard deviation (SD), coefficient of variation (CV) and variability independent of the mean (VIM). RESULTS: During a mean follow-up of 49 months, 22 (8.7%) events occurred. Visit-to-visit variability in Lp(a) was significantly higher in the MACE group compared to the non-MACE group. In the multivariate Cox analysis, only Lp(a)-related parameters were independent predictors for MACEs. The hazard ratios and 95% confidence intervals of each 1-SD increase of SD, CV, and VIM of Lp(a) were 1.42 (1.12-1.80), 1.50 (1.11-2.02) and 1.60 (1.16-2.22), respectively. Kaplan-Meier analysis revealed that patients with higher Lp(a) variability presented lower event-free survival. The results were consistent in various subgroups. CONCLUSIONS: Our study firstly suggested that Lp(a) variability was associated with MACEs in real-world patients with FH, which emphasized the importance of regular lipid monitoring in the patients with high risk. 2021 Annals of Translational Medicine. All rights reserved.
Authors: Sripal Bangalore; Andrei Breazna; David A DeMicco; Chuan-Chuan Wun; Franz H Messerli Journal: J Am Coll Cardiol Date: 2015-04-21 Impact factor: 24.094
Authors: Anne Langsted; Pia R Kamstrup; Marianne Benn; Anne Tybjærg-Hansen; Børge G Nordestgaard Journal: Lancet Diabetes Endocrinol Date: 2016-05-13 Impact factor: 32.069
Authors: M Seed; F Hoppichler; D Reaveley; S McCarthy; G R Thompson; E Boerwinkle; G Utermann Journal: N Engl J Med Date: 1990-05-24 Impact factor: 91.245
Authors: Elvira O Gosmanova; Margit K Mikkelsen; Miklos Z Molnar; Jun L Lu; Lenar T Yessayan; Kamyar Kalantar-Zadeh; Csaba P Kovesdy Journal: J Am Coll Cardiol Date: 2016-09-27 Impact factor: 24.094
Authors: Marcio H Miname; Marcio Sommer Bittencourt; Sérgio R Moraes; Rômulo I M Alves; Pamela R S Silva; Cinthia E Jannes; Alexandre C Pereira; José E Krieger; Khurram Nasir; Raul D Santos Journal: JACC Cardiovasc Imaging Date: 2018-11-15
Authors: Brian A Ference; Henry N Ginsberg; Ian Graham; Kausik K Ray; Chris J Packard; Eric Bruckert; Robert A Hegele; Ronald M Krauss; Frederick J Raal; Heribert Schunkert; Gerald F Watts; Jan Borén; Sergio Fazio; Jay D Horton; Luis Masana; Stephen J Nicholls; Børge G Nordestgaard; Bart van de Sluis; Marja-Riitta Taskinen; Lale Tokgözoglu; Ulf Landmesser; Ulrich Laufs; Olov Wiklund; Jane K Stock; M John Chapman; Alberico L Catapano Journal: Eur Heart J Date: 2017-08-21 Impact factor: 29.983